SCHEMBL4352298

SCHEMBL4352298

CC(C)C(NC[C@@H](O)[C@H](Cc1ccc(OCCN)cc1)NC(=O)O)S(=O)(=O)c1ccc2c(c1)OCO2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.38
ABCB1 P08183 1/20 0.38
ALDH1A1 P00352 5/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
ADRB3 P13945 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914161 0.95 ITGB3 (0.40) HTTABCB1ALDH1A1MAPTRAB9A
SCHEMBL4347480 0.90 MAOA (0.44) HTTABCB1ALDH1A1MAPT
SCHEMBL6051065 0.89 MAOB (0.42) HTTABCB1ALDH1A1NPC1RAB9A
SCHEMBL4352403 0.88 ABCB1 (0.39) HTTABCB1ALDH1A1MAPTLMNA
SCHEMBL6051143 0.85 ABCB1 (0.36) HTTABCB1ALDH1A1MAPTLMNA
SCHEMBL6051151 0.85 ABCB1 (0.35) HTTABCB1ALDH1A1MAPTKDM4E
SCHEMBL6436803 0.84 ADAMTS4 (0.44) ABCB1NPC1RAB9A
SCHEMBL6913199 0.84 ADAMTS4 (0.46) HTTABCB1ALDH1A1NPC1RAB9A
SCHEMBL6051171 0.82 ALDH1A1 (0.41) HTTALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL4344201 0.81 ABCB1 (0.55) ABCB1LMNAADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 HTT 1847/4885ABCB1 628/4885ALDH1A1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.